Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;70(3):e30153.
doi: 10.1002/pbc.30153. Epub 2023 Jan 10.

Advances in the clinical management of high-risk Wilms tumors

Michael V Ortiz  1 , Christa Koenig  2 , Amy E Armstrong  3 , Jesper Brok  4   5 , Beatriz de Camargo  6 , Annelies M C Mavinkurve-Groothuis  7 , Thelma B Velasquez Herrera  8 , Rajkumar Venkatramani  9 , Andrew D Woods  10 , Jeffrey S Dome  11 , Filippo Spreafico  12
Affiliations
Review

Advances in the clinical management of high-risk Wilms tumors

Michael V Ortiz et al. Pediatr Blood Cancer. 2023 Mar.

Abstract

Outcomes are excellent for the majority of patients with Wilms tumors (WT). However, there remain WT subgroups for which the survival rate is approximately 50% or lower. Acknowledging that the composition of this high-risk group has changed over time reflecting improvements in therapy, we introduce the authors' view of the historical and current approach to the classification and treatment of high-risk WT. For this review, we consider high-risk WT to include patients with newly diagnosed metastatic blastemal-type or diffuse anaplastic histology, those who relapse after having been initially treated with three or more different chemotherapeutics, or those who relapse more than once. In certain low- or low middle-income settings, socio-economic factors expand the definition of what constitutes a high-risk WT. As conventional therapies are inadequate to cure the majority of high-risk WT patients, advancement of laboratory and early-phase clinical investigations to identify active agents is urgently needed.

Keywords: COG; SIOP; Wilms tumor; high risk; nephroblastoma; relapsed.

PubMed Disclaimer

References

REFERENCES

    1. Dome JS, Graf N, Geller JI, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015;33(27):2999-3007. https://doi.org/10.1200/jco.2015.62.1888
    1. Dome JS, Mullen EA, Dix DB, et al. Impact of the first generation of Children's Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw. 2021;19(8):978-985. https://doi.org/10.6004/jnccn.2021.7070
    1. Green DM, Beckwith JB, Breslow NE, et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1994;12(10):2126-2131.
    1. Daw NC, Chi YY, Kalapurakal JA, et al. Activity of vincristine and irinotecan in diffuse anaplastic Wilms tumor and therapy outcomes of stage II to IV disease: results of the Children's Oncology Group AREN0321 study. J Clin Oncol. 2020;38(14):1558-1568. https://doi.org/10.1200/JCO.19.01265
    1. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312-7321. https://doi.org/10.1200/JCO.2005.01.2799

Publication types

LinkOut - more resources